Clinical Insights Drive BiVictriX's Approach To Targeted Cancer Therapies
Listed On AIM
Executive Summary
The UK biotech BiVictriX has completed a fundraising and listing on the UK’s AIM to support the development of antibody drug conjugates with “twin-antigen” targeting that could improve the selectivity of cancer therapeutics, with its lead candidate going up against acute myeloid leukemia.